CLEANCLINIC ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  2.3% 2.3% 2.3% 2.3% 2.3%  
Bankruptcy risk  4.2% 5.1% 5.9% 7.6% 6.0%  
Credit score (0-100)  50 43 38 31 38  
Credit rating  BBB BBB BBB BB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6

Net sales  0 0 0 0 0  
Gross profit  309 187 64.9 84.3 73.2  
EBITDA  126 -58.0 -57.5 84.3 73.2  
EBIT  126 -58.0 -57.5 84.3 73.2  
Pre-tax profit (PTP)  126.4 -59.6 -63.0 83.8 73.2  
Net earnings  97.7 -47.1 -49.7 64.4 53.7  
Pre-tax profit without non-rec. items  126 -59.6 -63.0 83.8 73.2  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  225 80.7 31.0 95.5 149  
Interest-bearing liabilities  2.7 61.1 103 49.4 48.4  
Balance sheet total (assets)  642 278 213 182 238  

Net Debt  -285 -81.0 -27.7 -64.2 -147  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  309 187 64.9 84.3 73.2  
Gross profit growth  158.7% -39.6% -65.2% 29.9% -13.1%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  642 278 213 182 238  
Balance sheet change%  90.8% -56.6% -23.3% -15.0% 31.1%  
Added value  126.4 -58.0 -57.5 84.3 73.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  2.0 -1.0 -2.0 1.0 2.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  40.9% -31.0% -88.5% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  25.9% -12.6% -23.4% 42.7% 35.0%  
ROI %  68.0% -31.4% -41.7% 60.5% 42.8%  
ROE %  55.5% -30.8% -88.9% 101.9% 43.9%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  35.1% 29.0% 14.5% 52.6% 62.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -225.6% 139.7% 48.2% -76.1% -200.2%  
Gearing %  1.2% 75.7% 330.9% 51.7% 32.5%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 5.3% 6.8% 0.6% 0.3%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  1.3 0.8 1.0 1.9 2.5  
Current Ratio  1.5 1.3 1.1 2.0 2.6  
Cash and cash equivalent  287.9 142.1 130.4 113.6 195.0  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  216.8 60.1 22.9 87.4 141.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0